Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-04-02 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
独立董事工作制度（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled "独立董事工作制度（草案）" which translates to "Independent Director Work System (Draft)" and contains detailed governance rules and procedures related to independent directors of the company. It references various laws, regulations, and listing rules applicable to the company, and outlines the duties, nomination, election, independence criteria, meetings, and working conditions of independent directors. There is no financial data, earnings information, audit results, or capital/financing updates. The content is focused on governance structure and internal rules regarding board members, specifically independent directors. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy (8686 characters) and is not a brief announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CGR with high confidence.
2026-04-02 Chinese
神州细胞关于变更独立董事及调整董事会专门委员会委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding changes in independent directors and adjustments to the board's specialized committees. It details the resignation of an independent director, the nomination of a new independent director candidate, and the reorganization of board committees. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on board and management changes, which fits the category of Board/Management Information (MANG). The document length is 1700 characters, which is short and typical for such announcements. Therefore, the appropriate classification is MANG with high confidence.
2026-04-02 Chinese
股东会议事规则（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled as "股东会议事规则（草案）" which translates to "Shareholders Meeting Rules (Draft)". It extensively details the procedures, rules, and regulations governing the conduct of shareholders' meetings, including the calling of meetings, voting procedures, rights and qualifications of shareholders, meeting records, and execution of resolutions. There is no indication that this is an announcement of a meeting, a voting result, or a report of financial results. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is a full document rather than a brief announcement. Therefore, the appropriate classification is CGR with high confidence.
2026-04-02 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司新增募投项目实施主体的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the addition of a new implementation entity for a fundraising project by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes specifics about the fundraising amount, use of funds, regulatory compliance, and board approval. The document references regulatory approvals, fundraising details, and internal governance related to the use of raised funds. It is not a full financial report like an Annual or Interim Report, nor is it a simple announcement or certification. It is a regulatory filing related to fundraising and compliance but does not fit into categories like Capital/Financing Update (CAP) because it is a verification opinion by the sponsor on the fundraising project implementation entity. Given the nature and content, it best fits under Regulatory Filings (RNS) as a compliance and verification document that does not neatly fit into other categories.
2026-04-02 Chinese
神州细胞第三届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It focuses on the approval and planning of the company's issuance of H shares and listing on the Hong Kong Stock Exchange. The content includes detailed descriptions of the issuance plan, authorization of board members, appointment of intermediaries, amendments to governance documents, and other related corporate governance matters. It is not a financial report, earnings release, or audit report. It is not a simple announcement of voting results but a comprehensive board meeting resolution document. The document is lengthy (15,000 characters) and contains substantive content about board decisions and governance related to capital raising and listing. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management, including major corporate actions like share issuance and listing approvals by the board.
2026-04-02 Chinese
独立董事提名人声明与承诺(徐建辉)
Regulatory Filings
2026-04-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.